US giant Gilead has just bought Kite (a biotech founded by Israel’s Arie Belldegrun) for $11.9 billion.  Kite’s CAR-T technology was developed by Weizmann Institute’s Professor Zelig Eshhar. A patient’s own immune system T-cells are genetically engineered to attack tumors.

http://www.globes.co.il/en/article-israeli-investors-profit-from-119b-kite-acquisition-1001202841

https://www.timesofisrael.com/breakthrough-israeli-cancer-professor-on-prowl-to-ease-other-ills/